

*Alessandra di Pietro, MD, PhD*  
**Curriculum Vitae et Studiorum**

---

---

## Curriculum vitae

Date of birth: April 1, 1978

Marital status: Engaged

Nationality: Italian

Current address: [REDACTED]  
[REDACTED]

Italian address: [REDACTED]  
[REDACTED]

US Cell phone: [REDACTED]

Italian Cell phone: [REDACTED]

E-mail: [REDACTED]  
[REDACTED]

Mother Language: Italian

Spoken Languages: English, Dutch, Spanish; French

### Current Position

Associate Director, Clinical Development Oncology at MedImmune LLC, Gaithersburg, MD, USA

### Education

- November, 16<sup>th</sup> 2009. Medical Oncology MD, PhD graduation.

Thesis: "*Role of Apoptosis Pathways Chemosensitivity of Testicular Germ Cell Tumours*", defensors Prof. Dr. E. G. E. de Vries, dr. J. A. Gietema, co-defensor: dr. S. de Jong, Department of Medical Oncology, UMCG, Groningen, The Netherlands

- November 2006- November 2009: PhD, University Medical Center Groningen (UMCG), Groningen, The Netherlands

- November, 9<sup>th</sup> 2006 Medical Oncology Graduation. 50/50 Magna Cum Laude at Università Cattolica del Sacro Cuore, Rome, Italy

Thesis: "*Testicular Germ Cell Tumours, a paradigm of chemosensibility for solid tumours*", defensor Prof. Dr. A. R.M Cittadini, supervisor Prof. Dr. E. G.E. de Vries.

- November 2002- November 2006: Recidency in Medical Oncology at Università Cattolica del Sacro Cuore, Rome, Italy

- July, 24<sup>th</sup> 2002: Medicine and Surgery Graduation - 110/110 Magna Cum Laude and Notable Mention, at Università Cattolica del Sacro Cuore, Rome, Italy.

Thesis: "Molecular evaluation of the correlation between susceptibility factors and precocious alterations in superficial bladder cancer, by means of a non-invasive method", defensor Prof. Dr. G. Flamini, co-defensor Prof. Dr. A. R. M. Cittadini, Oncology Department.

- October 1996- July 2002 Medical School at Università Cattolica Sacro Cuore, Rome, Italy

- 1991-1996: Secondary School Diploma, Benevento (60/60), at the Gymnasium Licaeum “Pietro Giannone”, Benevento, Italy

### **Further education**

- April 2010: Advanced Life Support-D intensive training, organized by IRC (Italian Resuscitation Council) at IEO, Milan, Italy
- November 2007: Basic Life Support-Defibrillator intensive training; organized by IRC (Italian Resuscitation Council) at Cardiological Hospital “Monzino”, Milan, Italy
- January 2007: SPSS Statistics Intensive training, UMCG Groningen, The Netherlands
- November 2005: Automatisation for Physicians, UMCG Groningen, The Netherlands
- July 2004: Evidence Based Oncology Intensive Training, organized by ESO (European School of Oncology), Antwerp, Belgium
- March 2004: VTM course for Safe Microbiological Techniques, UMCG Groningen, The Netherlands
- May 2002: Basic Life Support (BLS) - B category intensive training (final exam score:- Theoretic total score 100%, Practical total score 98%) organized by IRC (Italian Resuscitation Council) at Università Cattolica Sacro Cuore, Rome, Italy
- March 1999-November 2003: Internal student and, later-on, fellow at the Oncology Research Centre Giovanni XXIII - Università Cattolica del Sacro Cuore, Rome, Italy

### **Working experience**

- October 2011- currently: Associate Director, Clinical Development Oncology at MedImmune LLC, Gaithersburg, MD, USA

-Medical Leader for 2 checkpoint immune-modulators, currently in Phase II/III Trails as single agent and combination. Currently in charge for the development of these 2 products in the following areas: Breast, Mesothelioma, Melanoma, NSCLC. Medical lead for the same 2 compounds in combination with small molecules and chemotherapy in several Phase IB/II collaboration and ITT trials in solid tumours. Actively Involved in Clinical Development Plan of the products, preparation of the paperwork for regulatory affairs and FDA/ EMEA submission; directly responsible for writing and monitoring the company sponsored trials (Duties included eligibility, safety call management, site recruitment etc.); actively involved in the preparation of Adv Boards.

-Previously: Medical Leader for a Bite-Antibody Technology, currently in FTIH dose finding Trial in Gastro-intestinal tumours. Involved in Clinical Development Plan of the product, preparation of the paperwork for regulatory affairs and FDA submission; directly responsible for writing and monitoring the company sponsored trials; actively involved in the preparation of Adv Boards.

- July 2011-September 2011: Internal medicine expert at ER, MMSS “Casa di Cura Multi Medica” University Hospital, Sesto San Giovanni, Milan, Italy
- March 2010-September 2011: Internal medicine expert at ER, PSD “Policlinico Universitario San Donato”, San Donato Milanese, Milan, Italy



- October 2009- September 2011: Internist at RSA “Casa di Cura per Coniugi”, Milan, Italy
- May 2008-August 2011: Internist at FSM “Fondazione Salvatore Maugeri”, Cardio-Pulmonary rehabilitation and internal medicine rehabilitation, Milan, Italy
- June 2007-July 2011: Clinical researcher and clinical oncologist at Melanoma and Sarcomas Division and Medical Oncology Department, IEO “European Institute of Oncology”, Milan, Italy
  - Investigator for several Phase 1b through 3 programs in Melanoma and Breast cancer:
    - Ph. 3 DTIC + Ipilimumab vs DTIC + Placebo in first line unresectable Stage III-Stage IV melanoma patients (BMS)
    - Ph. 3 Ipilimumab vs Placebo in resected Stage III Melanoma (BMS)
    - Ph. 3 Anti-BRaf vs DTIC in first line unresectable Stage III-Stage IV melanoma B-Raf Melanoma Patients (Roche)
    - Ph. 3 MAGE-A3 vaccine vs Placebo as adjuvant treatment in resected stage III patients (GSK)
    - Ph. 3 MAGE-A3 vaccine vs DTIC/ TMZ in Stage IVa melanoma patients -PREDICT (GSK).
    - Ph.2/3 rec-PRAME vaccine in Stage IVa melanoma patients (GSK)
    - Ph.2 Ipilimumab + Fotemustine in pre-treated advanced melanoma patients (NIBIT)
    - Ph. 2 DTIC + Bevacizumab in first line Stage IV melanoma patients (Roche)
    - Ph. 3 Allovectin-7 vs DTIC/ TMZ in advanced melanoma patients (Vical).
    - E7080 vs Paclitaxel in pretreated unresectable Stage III-Stage IV melanoma (EISAI).
    - Ph.3 Nilotinib vs DTIC in first-line c-kit mutant unresectable Stage III-Stage IV melanoma patients (Novartis)
    - Ph.3 Masitinib vs DTIC in second line Stage III/IV c-kit mutant melanoma patients (AB Science).
    - Ipilimumab Expanded Access in pre-treated advanced melanoma patients.
    - Ph. 3 Abraxane vs DTIC in first line unresectable Stage III-Stage IV melanoma patients (Abraxis).
    - Ph.2 Mek-Inhibitor vs Taxol in first/second line B-Raf positive unresectable Stage III-Stage IV melanoma patients (GSK).
    - Ph. 1b Fotemustine + TMZ in unresectable Stage III-Stage IV melanoma (Italfarmaco).
    - Ph. 2 Oral Vinorelbine in heavily pre-treated advanced breast cancer patients
    - Ph.3 Taxol + Bevacizumab vs Taxol + Placebo in advanced breast cancer patients
    - Ph.3 Letrozole vs Anastrozole in the adjuvant treatment of post-menopausal hormone responsive breast cancer patients (Novartis).
    - Ph.2 biweekly Caelix in heavily pre-treated advanced breast cancer patients (ITT)

- Since November 2003: Collaboration with IMSW society, Paris France, for the translation of medical books from English into Italian
- Since November 2002, Collaboration with IMS society for Cancer Management and Marketing enquiries.
- January 2004-June 2007: Oncology translational researcher at Medical Oncology Research Laboratory, Department of Medical Oncology, UMCG, Groningen, The Netherlands
- July-October 2003: Oncology translational researcher at Medical Oncology Research Laboratory, Department of Medical Oncology, UMCG, Groningen, The Netherlands
- October 2001-October 2002: Tutoring and training to medical students at Università Cattolica del Sacro Cuore, Rome, Italy

### Other

- May 2007: Command of Dutch language, fourth level- Letters faculty RUG University, Groningen, The Netherlands
- July 2005: Command of Dutch language NT2 Staatsexaman “Nederlands Als Tweede Taal”, for all the four the subparts writing, speaking, listening and reading- IB Groep, Groningen, The Netherlands
- May 2005: Command of Dutch language, second level- letters faculty RUG University, Groningen, The Netherlands
- May 2004: Command of the Dutch language, first level - Letters Faculty RUG University, Groningen, The Netherlands
- May 2003: Winner of Residency in Oncology at National Cancer Institute, Milan, Italy
- April 2003: Winner of Residency in Oncology at Università Cattolica Sacro Cuore, Rome, Italy
- June 1996: Classic & Contemporary Dance Diploma, Dance School Academy, Benevento, Italy
- July 1994: Command of the English language at Bootham School of English, York, UK

### Scholarships & Prizes

- April 2009: December 200 April 2009: Abstract: “New Apoptosis Markers in Melanoma”. A. di Pietro, P.F.F. Ferrucci, A. Testori. AACR 2009. *Winner of BMS prize as best work of Clinical Research session.*
- November 2005: WEA (Working Experience Abroad) Scholarship, assigned from Università Cattolica “Sacro Cuore”- Rome, Italy
- November 2005: “Foundation for Education in Oncology”(Fondazione per la Formazione Oncologica) scholarship
- October 2005: Doctor Renato Russo Prize, as best young doctor of the year 2005, Ordine dei Medici e degli Odontoiatri, Benevento, Italy



- September 2005: Teaching ESO Oncology Scholarship, to attend the congress on Colorectal cancer, London 1-3 December 2005
- October 2004: Università Cattolica Sacro Cuore "Education Abroad" Scholarship
- March 2004: "Foundation for Education in Oncology" (Fondazione per la Formazione Oncologica) Scholarship
- November 2002: Leonardo da Vinci scholarship, in relation to the project L-WAY
- October 2002: FIRC (Italian Cancer Research Federation) Scholarship
- April 2002: Best student of the year Scholarship
- October 1996: INPDAP Scholarship

#### **Informatic Skills**

- Microsoft Office (Word, Ppt, Excel)
- Access
- Argos
- Sinfonia
- Sygma Plot
- SPSS ver. 12 & 14
- Acrobat Prof
- Reference Manager
- GraphPad
- Media Player/ Mediavideo

#### **Publications**

##### Articles:

**A Phase II randomized, double-blind, placebo-controlled study of tremelimumab for second – and third-line treatment in patients with unresectable pleural or peritoneal mesothelioma.** L. Calabro, L. M. Krug, A. di Pietro, S. Antonia, R. Hassan, R. Narwal, P. Robbins, D. Fu, A. Shalabi, H. Abdullah, R. Ibrahim, H. Kindler, M. Maio. 2013 JIC 2013; 1(Suppl !):P132.

**Pro- and anti-apoptotic effects of p53 in cisplatin-treated human testicular cancer are cell context-dependent.** di Pietro A, Koster R, Boersma-van Eck W, Dam WA, Mulder NH, Gietema JA, de Vries EG, de Jong S. Cell Cycle. 2012 Nov 19;11(24).

**Newly Identified Tumor Antigens as Promising Cancer Vaccine Targets for Malignant Melanoma treatment.** Ferrucci PF, Tosti G, di Pietro A, Passoni C, Pari C, Tedeschi I, Cataldo F, Martinoli C, Testori A. Curr Top Med Chem. 2012 Jan.

**The immunological era in melanoma treatment: new challenges for heat shock protein-based vaccine in the advanced disease.** di Pietro A, Tosti G, Ferrucci PF, Testori A. Expert Opin Biol Ther. 2011 Oct.



**Hormonal and reproductive factors in relation to melanoma in women: current review and meta-analysis.** Gandini S, Iodice S, Koomen E, Di Pietro A, Sera F, Caini S. Eur J Cancer. 2011 Nov.

**Cytoplasmic p21 expression levels determine cisplatin resistance in human testicular cancer.** Koster R, di Pietro A, Timmer-Bosscha H, Gibcus JH, van den Berg A, Suurmeijer AJ, Bischoff R, Gietema JA, de Jong S. J Clin Invest. 2010 Oct 1;120(10):3594-605.

**Electrochemotherapy for cutaneous and subcutaneous tumor lesions: a novel therapeutic approach.** Testori A, Tosti G, Martinoli C, Spadola G, Cataldo F, Verrecchia F, Baldini F, Mosconi M, Soteldo J, Tedeschi I, Passoni C, Pari C, Di Pietro A, Ferrucci PF. Dermatol Ther. 2010 Nov;23(6):651-61. Review.

**Presentation of multicentric trial about sentinel node identification with sentinella intraoperative gamma camera versus traditional gamma probe.** A. Testori, F. Verrecchia, J. Soteldo, A. Di Pietro, G. Spadola, G.C. Vitali, F. Cataldo, C. Pari and P.F. Ferrucci Melanoma Research: June 2010 - Volume 20 - Issue - p e52-53 doi: 10.1097/01.cmr.0000382853.14512.34 MELANOMA II: Surgery - Staging-Prognosis

**Meeting report from the Third Global Workshop on Melanoma.** Agarwala SS, di Pietro A, Flaherty KT, Garbe C, Grob JJ, Kashani-Sabet M, Kirkwood JM, Leachman S, Messina J, O'Day S, Ribas A, Sondak V. Pigment Cell Melanoma Res. 2010 Oct;23(5):e1-7.

**Metronomic administration of pegylated liposomal-doxorubicin in extensively pre-treated metastatic breast cancer patients: A mono-institutional case-series report.** Munzone E, Di Pietro A, Goldhirsch A, Minchella I, Verri E, Cossu Rocca M, Marengi C, Curigliano G, Radice D, Adamoli L, Nolè F. Breast. 2010

**Heat shock protein peptide complex 96-based vaccines in melanoma: How far we are, how far we can get.** di Pietro A\*, Tosti G\*, (\*) *Co-authors*, Ferrucci PF, Testori A. Hum Vaccin. 2009 Nov 23.

**HSPPC-96 vaccine in metastatic melanoma patients: from the state of the art to a possible future.** Tosti G\*, di Pietro A\*, (\*) *Co-authors*, Ferrucci PF, Testori A. Expert Rev Vaccines. 2009 Nov.

**Adjuvant therapy of melanoma.** Agarwala S. di Pietro A. AJHO May 2009 8, (5)

**Biology and clinical use of hit shock proteins GP96 in cancer patients.** G. Parmiani, A. M. Di Filippo, L. Pilla, C. Castelli, L. Rivoltini, M. Maio, M. Santinami, V. Mazzaferro, A. di Pietro, A. Testori. J Immunotherapy. *Submitted and accepted*

**Oncophage: step to the future for vaccine therapy in melanoma.** di Pietro A\*, Tosti G\*, (\*) *Co-authors*, Ferrucci PF, Testori A. Expert Opin Biol Ther. 2008 Dec;8(12):1973-84.

**Clinical evaluation of M30 and M65 ELISA cell death assays as circulating biomarkers in a drug-sensitive tumor, testicular cancer.** de Haas EC\*, di Pietro A\*, (\*) *Co-authors*, Simpson KL, Meijer C, Suurmeijer AJ, Lancashire LJ, Cummings J, de Jong S, de Vries EG, Dive C, Gietema JA. Neoplasia. 2008 Oct



✓ **Basosquamous carcinoma of the thoracic: A case report.** J Soteldo, L Jimenez, F Verrecchia, G Mazzarol, F De Lorenzi, F Baldini, A di Pietro, A Testori. Division of Melanoma and Sarcoma, European Institute of Oncology, Milan, Italy. The American Journal of Case Report. 2008; 9: 355-358

**The treatment of cutaneous and subcutaneous lesions with electrochemotherapy with bleomycin** J. Soteldo, A. di Pietro, G. Tosti, M. Mosconi, F. Baldini, M. Rastrelli, G. Spadola, G. F. Verrecchia and A. Testori. Division of Melanoma and Sarcoma, European Institute of Oncology, Milan, Italy. Internet Article April 2008. [http://www.gmmm.com.ve/articulos\\_01-2010/art\\_treatmentCutaneous.htm](http://www.gmmm.com.ve/articulos_01-2010/art_treatmentCutaneous.htm)

**Testicular germ cells Tumours: the paradigm of chemo- sensitive solid tumour,** di Pietro A, de Vries EGE, Gietema JA, Spierings. DCJ and de Jong, S. - Int J Bio Cell Biol 37 (2005) 2437-2456.

Abstracts:

AACR 2013

✓ **A Phase II randomized, double-blind, placebo-controlled study of tremelimumab for second – and third-line treatment in patients with unresectable pleural or peritoneal mesothelioma.** L. Calabro, L. M. Krug, A. di Pietro, S. Antonia, R. Hassan, R. Narwal, P. Robbins, D. Fu, A. Shalabi, H. Abdullah, R. Ibrahim, H. Kindler, M. Maio.

AACR 2011

**B-Raf, c-KIT, VEGFR and MGMT Expression Analysis in Advanced Melanoma (MM) Patients (pts) Treated With Dacarbazine (DTIC) + Bevacizumab (B): correlation with response and survival.** A. di Pietr<sup>1</sup>, M. Barberis<sup>\*</sup>, C. Martinoli, M. Manzottt, C. Passoni, C. Pari, M. Mosconi, F. Cataldo, S. Gandini, A. Testori, P.F. Ferrucci

**The M-SKIP Project: an international pooled-analysis on melanocortin-1 receptor (MC1 R) variants and skin carcinogenesis.** S. Gandini, A. di Pietro, P. Maisonneuve, P. Autier, M. C. Fargnoli, J. C. García-Borrón, J. Han, P. A. Kanetsky, M. T. Landi, J. Little, J. Newton-Bishop, F. Sera and Sara Raimondi

EORTC-MG Perspectives, Amsterdam 2010

**Evaluation of maspin expression in primary tumors of melanoma patients: evidences for prognostic significance.**

ASCO Annual Meeting 2010, Chicago June 2010

**Dacarbazine (DTIC) + Bevacizumab (B) in Chemotherapy (CTh)-naïve Advanced Melanoma (MM) Patients (pts): a Phase II Study** A. di Pietro<sup>\*1</sup>, P.F. Ferrucci<sup>\*1</sup>, E. Munzone<sup>\*</sup>, M. Mosconi, S. Gandini, C. Pari, F. Cataldo, F. Nolè, I. Minchella, A Testori



**Electrochemotherapy with bleomycin: a local treatment with possible systemic implication.** A. Testori; F. Verrecchia; J. Soteldo; P.F. Ferrucci; C. Martinoli; S. Gandini; A. di Pietro

ASCO Annual Meeting 2009, Orlando June 2009

**Circulating endothelial cells (CECs), progenitors (CEPs), and circulating tumor cells (CTCs) for prediction of response in patients with advanced breast cancer (ABC) receiving metronomic oral vinorelbine (oV): Preliminary results.** F. Nole, E. Munzone, F. Bertolini, M. T. Sandri, G. Petralia, L. Adamoli, D. Radice, D. Cullura, A. di Pietro, A. Goldhirsch; European Institute of Oncology, Milan, Italy

EORTC-MG Spring 2009, Bruxelles March 2009:

**Role of the SOS-1-Rac signalling pathway in melanoma progression** A. di Pietro, G. Tosti, S. Gerboth, A. Palamidessi, C. Loise, G. Mazzarol, P. P. Di Fiore, P.F. Ferrucci, A. Testori, G. Scita

AACR 2009, Denver April 2009:

**Apoptosis markers: A feasible tool to improve prognosis definition and to define therapy response in melanoma** A. di Pietro, P.F. Ferrucci, G. Mazzarol, A. Testori

EORTC Fall 2009, Leeds October 2009:

**Characterization of cytokeratin 18 expression in malignant melanoma cells: evaluation of a novel biomarker to monitor therapy response.** A. di Pietro, C. Martinoli, P.F. Ferrucci, A. Testori

XXI National Congress of Società Polispecialistica Italiana Giovani Chirurghi, June 2008:

**A Retrospective Review of Sentinel Node Biopsy for High-Risk Cutaneous Non-Anogenital Squamous Cell Carcinoma,** M. Rastrelli, M. Zonta, J. Soteldo, F. Verrecchia, G. Tosti, G. Spadola, A. di Pietro, A. Testori. Division of Melanoma and Sarcoma, European Institute of Oncology, Milan, Italy.

1<sup>st</sup> World Meeting of Interdisciplinary Melanoma Centers, Barcelona, Spain, Sept 2007

**New markers of apoptosis: a feasible tool to improve prognostic accuracy and to monitor therapeutic response in melanoma patients.** di Pietro A, Zonta M., Jimenez L., Tosti G., Ferrucci P.F., Mazzarol G., Testori A.

**Safety, feasibility and toxicity profile of a new immunotherapy protocol for metastatic melanoma patients using in vivo Salmonella typhimurium vaccination and treatment.** P. F. Ferrucci, C. Martinoli, A. di Pietro, M. Rastrelli, A. Testori, M. Rescigno

**Atypical Spitz nevus and Spitz tumour: a report of 14 cases.** G. Tosti, L. Jimenez, A. di Pietro, A. Testori, G. Mazzarol

5<sup>th</sup> Apoptosis Meeting, "Death between the tulips", Kerkrade, The Netherlands, May 2006

**The p53 pathway effects on cisplatin-induced apoptosis in Testicular Germ Cell Tumours cell lines, depending on the cellular context.** A. di Pietro, R. Koster, J. A. Gietema, S. de Jong

AACR 2007

**Utility of circulating biomarkers of cell death in disseminated testicular cancer patients treated with standard platinum-based chemotherapy.** K. Taylor, E. de Haas, A. di Pietro, C. Meijer, L. Lancashire, J. Cummings, S. de Jong, E. de Vries, C. Dive, J. Gietema.

97<sup>th</sup> AACR Annual Meeting, Washington, D.C., USA

**p21<sup>Cip1/Waf1</sup> over-expression protects human testicular germ cell tumour cells from cisplatin induced apoptosis.** R. Koster, A. di Pietro, H. Timmer-Bosscha, H. Schepers, R. Bischoff, J. A. Gietema, S. de Jong

#### Submitted and Accepted Articles

**The p53 pathway affects cisplatin-induced apoptosis in human testicular germ cell lines depending on the cellular context** A. di Pietro, R. Koster, W.A. Dam, N.H. Mulder, J. A. Jourik, E.G. E. de Vries, S. de Jong, *Oncogene; Submitted*

#### Invited speaker

- January 2011: Ground Rounds for ECM, IEO, Milan Italy. "Melanoma and Cellular Senescence: *a possible step forward in Melanoma treatment?*"
- September 2010: EORTC-Melanoma Group Meeting, Amsterdam, NI. "Dacarbazine (DTIC) + Bevacizumab (B) in Chemotherapy (CTh)-naïve Advanced Melanoma (MM) Patients (pts): a Phase II Study"
- January 2010: Ground Rounds for ECM, IEO, Milan Italy. "Anti-angiogenesis: a promising path in the treatment of advanced melanoma"
- November 2009: Faculty Panel Member at Premeeting Third Global Workshop on Malignant Melanoma, Berlin Germany. "Intra-lesional treatment options in melanoma"
- October 2009: EORTC- Melanoma Group Meeting, Leeds, UK. "Characterization of Cytokeratin 18 expression in malignant melanoma cells: evaluation of a novel biomarker to monitor therapy response"
- October 2009: IMI- Italian Melanoma Intergroup Annual Meeting 2009, Genoa Italy. "New Therapy Protocols in Advanced Melanoma"
- March 2009: EORTC-Melanoma Group Meeting, Bruxelles Belgium. "Role of the SOS-1 Rac signalling pathway in melanoma progression"



- September 2008: Ground Rounds for ECM, IEO, Milan Italy. "Anti-CTLA4 Treatment in metastatic Melanoma: IEO experience".
- June 2008: ICATMM-EADO Meeting 2008, Marseille, France. "Combining chemotherapy and targeted therapy".
- June 2008: ICATMM-EADO Meeting 2008, Marseille, France. "New apoptosis markers: a feasible tool to improve prognosis definition and to define therapy response"
- January 2008: "Insieme oltre la malattia" (Together beyond cancer disease), Belluno Italy
- November 2007: Diagnosis and treatment of malignant melanoma. "Adjuvant therapy in Melanoma" & "Advanced Melanoma Management", Caracas Venezuela
- October 2005: "Cancers in the Elderly" Telesse Terme, Benevento, Italy. "Bladder cancer"

**Leisure activities**

- Philosophy & Foreign Languages
- Italian, Greek and Latin Literatures
- Tango and Caribbean Dances (Competition Level)
- Aerobics and fitness
- Reading, travelling
- Volunteer at reception centers for poor people

